Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 1% - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 1% during trading on Tuesday . The stock traded as high as $7.25 and last traded at $7.06. Approximately 7,639,385 shares were traded during mid-day trading, an increase of 12% from the average daily volume of 6,791,037 shares. The stock had previously closed at $6.99.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RXRX. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Finally, Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Up 3.6 %

The stock has a 50 day moving average price of $6.76 and a 200 day moving average price of $7.16. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the previous year, the firm posted ($0.43) earnings per share. The firm's quarterly revenue was up 147.6% compared to the same quarter last year. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,697,960.96. This trade represents a 2.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 107,788 shares of company stock worth $724,691 over the last three months. 15.75% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC increased its position in shares of Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. State Street Corp grew its stake in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. FMR LLC raised its position in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after buying an additional 656,003 shares in the last quarter. Finally, Lingotto Investment Management LLP boosted its stake in shares of Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company's stock worth $27,563,000 after buying an additional 1,500,000 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.